The COLT trial is an investigator-driven, multicenter, non-randomized, open-label, controlled, prospective, parallel trial, aimed at assessing the efficacy (in terms of overall survival: OS) of liver transplantation (LT) in liver-only CRC metastases, compared with a matched cohort of patients bearing the same tumor characteristics, collected during the same time period and included in a phase III Italian RCT on triplet chemotherapy+antiEGFR
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
22
Liver transplant from cadaveric donors
mFOLFOX
Panitumumab
SOD Clinica di Chirurgia Epatobiliare, Pancreatica e dei Trapianti e SC di Oncologia Medica, Ospedali Riuniti di Ancona
Ancona, Italy
NOT_YET_RECRUITINGASST Papa Giovanni XXIII
Bergamo, Italy
NOT_YET_RECRUITINGChirurgia EBP e dei Trapianti di Fegato e SC di Oncologia Medica, Ospedale Policlinico San Martino
Genova, Italy
NOT_YET_RECRUITINGFondazione IRCCS Istituto NAzionale Tumori di Milano
Milan, Italy
RECRUITINGOspedale Maggiore di Milano Policlinico
Milan, Italy
RECRUITINGAzienda Ospedaliera Ospedale Niguarda Ca' Granda
Milan, Italy
NOT_YET_RECRUITINGIstituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT)
Palermo, Italy
RECRUITINGGONO Group (Gruppo Oncologico Nord Ovest) TRIPLETE Trial Coordination
Pisa, Italy
RECRUITINGFondazione Policlinico Universitario A.Gemelli IRCCS
Roma, Italy
NOT_YET_RECRUITINGOspedale Universitario Molinette S. Giovanni Battista di Torino
Torino, Italy
RECRUITING...and 2 more locations
Overall Survival
Time from enrolement to either death or censoring
Time frame: 5 years
Progression Free Survival
Time from enrolement to either progression or censoring
Time frame: 5 years
Complications rate
Complications according to Dindo Clavien Classification
Time frame: 90 days after liver transplant
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.